Nagourney Cancer Institute Challenges “Death Sentence” Mindset in Stage 4 Pancreatic Cancer

In this episode of Global Economic Press, Alex Brady discusses a groundbreaking development in the treatment of stage 4 pancreatic cancer by the Nagourney Cancer Institute. The institute is challenging the traditional "death sentence" mindset associated with this lethal diagnosis by offering innovative approaches that provide new hope and potentially life-saving treatments. The discussion highlights how the institute's technology, developed in Southern California, is offering durable benefits and even cures in advanced cases of pancreatic cancer. By studying pancreatic cancer cells in their natural state, the institute can predict how patients will respond to chemotherapy and targeted agents, thus improving treatment outcomes. The Nagourney Cancer Institute employs a comprehensive approach to drug selection, starting with National Comprehensive Cancer Network-guideline and Food and Drug Administration-approved drugs, and expanding to novel combinations and experimental drugs. This method has shown that pancreatic cancer is not necessarily a death sentence when patients have access to the most effective treatments for their tumors. The institute's work is supported by a 2023 meta-analysis that reported significantly higher response and survival rates. With new drugs targeting common mutations like KRAS and calls for a "Manhattan Project" to accelerate patient-specific strategies, the institute is at the forefront of offering hope to patients with one of the deadliest cancer diagnoses. For more information, visit the Nagourney Cancer Institute's website at https://nagourneycancerinstitute.com/.